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Objectives: To determine antibiotic susceptibility in isolates of Streptococcus pneumoniae and Haemophilus
influenzae collected in 2014–16 from Ukraine and the Slovak Republic.
Methods: MICs were determined by CLSI broth microdilution and susceptibility was assessed using CLSI, EUCAST
and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
Results: S. pneumoniae isolates collected in Ukraine (n"100) showed susceptibility rates 97% for amoxicillin,
amoxicillin/clavulanic acid, penicillin [intravenous (iv) non-meningitis] and fluoroquinolones, between 83% and
86% for oral penicillin, macrolides and cefaclor, and 75% for trimethoprim/sulfamethoxazole. Susceptibility was
substantially lower in the Slovak Republic (n"95). All isolates were susceptible to the fluoroquinolones, but sus-
ceptibility to penicillin, amoxicillin, amoxicillin/clavulanic acid, cefuroxime and trimethoprim/sulfamethoxazole
varied between 61% and 64%, with only 44% of isolates susceptible to the macrolides. Susceptibility of
H. influenzae was more homogeneous, with susceptibility to amoxicillin/clavulanic acid, ceftriaxone, cefuroxime,
azithromycin and the fluoroquinolones seen in .90% of isolates by CLSI criteria in both countries. Much greater
variability was seen across breakpoints, especially for azithromycin, cefaclor and cefuroxime. The b-lactamase
rate was 5.1% (5/98) in the Slovak Republic and 7.3% (7/96) in Ukraine, but the Slovak Republic also had a rela-
tively high rate of b-lactamase-negative-ampicillin-resistant (BLNAR) isolates (7.1%; 7/98).
Conclusions: The variability found across these two neighbouring countries illustrates the need to monitor and
publish national and local resistance patterns. This information is not only critical for effective empirical therapy
but can also be used to help shape and support antimicrobial stewardship efforts in order to limit antibiotic
resistance.
Introduction
In 2015, lower respiratory infections remained the most deadly
communicable disease and the third leading cause of death world-
wide with 3.2 million deaths.1 Even in Europe, where mortality due
to communicable diseases is much lower than in many other re-
gions of the world, these infections still represent the sixth most
common cause of death.1 It is therefore critical that decisions re-
garding antimicrobial therapy, which is typically empirical for lower
respiratory infections, are supported by solid surveillance data of
local antimicrobial resistance patterns. This is especially important
since surveillance studies have shown that resistance levels can
vary substantially across countries and even between institutions
in the same country.2–5 Monitoring and reporting of local
resistance rates can be undertaken by individual hospitals and lab-
oratories as well as through larger surveillance studies that can fa-
cilitate comparative analyses across regions and longitudinal
analyses over time. The Survey of Antibiotic Resistance (SOAR) is
an international antimicrobial resistance surveillance study that
focuses on key respiratory pathogens and has been running since
2002 in the Middle East, Africa, Latin America, Asia-Pacific and
Commonwealth of Independent States countries. For this report,
recent SOAR data from hospitals in the Slovak Republic and
Ukraine were analysed to provide a picture of the current state of
antimicrobial susceptibility of Streptococcus pneumoniae and
Haemophilus influenzae, two important bacterial pathogens asso-
ciated with lower respiratory tract infections.
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Materials and methods
Collaborating centres
The following centres took part in the study: one from the Slovak Republic
(Hospital Nitra, Nitra) and two from Ukraine (Diagnostic Center of Medical
Academy, Dnipropetrovsk, and National Institute of Phthisiology and
Pulmonology, Kiev).
Isolates of H. influenzae and S. pneumoniae from community-acquired
respiratory tract infections were sent to a central laboratory (International
Health Management Associates, Inc., Switzerland) where they were sub-
cultured and re-identified. H. influenzae were re-identified by MALDI-TOF
MS methodology and S. pneumoniae identity was confirmed by optochin
susceptibility and bile solubility. b-Lactamase production was determined
for each H. influenzae isolate by a chromogenic cephalosporin (nitrocefin)
disc method. Duplicate isolates from the same patient were not accepted.
Susceptibility testing
Isolates were evaluated for antibiotic susceptibility using broth microdilu-
tion methodology recommended by the Clinical and Laboratory Standards
Institute (CLSI).6
Both pathogens were assessed for susceptibility to amoxicillin, amoxicil-
lin/clavulanic acid (2:1), azithromycin, cefaclor, ceftriaxone, cefuroxime,
clarithromycin, erythromycin, levofloxacin, moxifloxacin and trimethoprim/
sulfamethoxazole (1:19). S. pneumoniae was also tested for susceptibility
to penicillin whereas H. influenzae was additionally tested for susceptibility
to ampicillin.
Susceptibility to the study drugs was calculated based on CLSI break-
points, EUCAST breakpoints and pharmacokinetic/pharmacodynamic
(PK/PD) breakpoints.7–9 These breakpoints are shown in Table 1.
Quality control and data analysis
Quality control strains S. pneumoniae ATCC 49619, Escherichia coli ATCC
25922, H. influenzae ATCC 49247, H. influenzae ATCC 49766 and E. coli ATCC
32518 were included on each day of testing. Results of susceptibility testing
were accepted if the results of the control strains were within published
limits. Differences in susceptibility (using CLSI criteria) across age groups,
source of infection and penicillin susceptibility (S. pneumoniae only) were
assessed for statistical significance (where n20) with Fisher’s exact test
using XLSTAT version 2011.1.05. A P value ,0.05 was considered statistic-
ally significant.
Results
S. pneumoniae isolates
A total of 195 S. pneumoniae isolates were collected from three
centres in the Slovak Republic and Ukraine from 2014 to 2016.
Most pneumococci came from sputum (n"60; 30.8%) and bron-
choalveolar lavage (n"56; 28.7%). Less frequently, isolates were
from sinuses (n"35; 17.9%), middle ear effusion (n"20; 10.3%),
endotracheal aspirate (n"5; 2.6%) and blood (n"3; 1.5%).
Sixteen isolates were from an undisclosed respiratory source
Table 1. MIC breakpoints (mg/L) used for S. pneumoniae and H. influenzae isolates
S. pneumoniae H. influenzae
CLSI EUCAST CLSI EUCAST
Antimicrobial S I R S I R S I R S I R
PK/PD
(S only)
Amoxicillin 2 4 8 NA NA NA NA NA NA 2 – 4 2 (4)
AMCa 2 4 8 NA NA NA 4 – 8 2 – 4 2 (4)
Ampicillin NA NA NA NA NA NA 1 2 4 1 – 2 NA
Azithromycin 0.5 1 2 0.25 0.5 1 4 – – 0.12 0.25–4 8 0.12
Cefaclor 1 2 4 0.03 0.06–0.5 1 8 16 32 NA NA NA 0.5
Ceftriaxone 1 2 4 0.5 1–2 4 2 – – 0.12 – 0.25 1
Cefuroximeb 1 2 4 0.25 0.5 1 4 8 16 0.12 0.25–1 2 1
Clarithromycin 0.25 0.5 1 0.25 0.5 1 8 16 32 1 2–32 64 0.25
Erythromycin 0.25 0.5 1 0.25 0.5 1 NA NA NA NA NA NA 0.25
Levofloxacin 2 4 8 2 – 4 2 – – 0.06 – 0.12 2
Moxifloxacin 1 2 4 0.5 – 1 1 – – 0.12 – 0.25 2
Penicillin (iv non-meningitis) 2 4 8 NAc NAc NAc NA NA NA NA NA NA NA
Penicillin (oral) 0.06 0.12–1 2 0.06 0.12–2 4 NA NA NA NA NA NA NA
SXTd 0.5 1–2 4 1 2 4 0.5 1–2 4 0.5 1 2 0.5
AMC, amoxicillin/clavulanic acid; SXT, trimethoprim/sulfamethoxazole; S, susceptible; I, intermediate; R, resistant; NA, not applicable.
aAmoxicillin/clavulanic acid was tested at a 2:1 amoxicillin to clavulanic acid ratio; breakpoints are expressed as the amoxicillin component. PK/PD
breakpoints based on high dose (4 g of amoxicillin with 250 mg of clavulanate per day for adults) shown in parentheses,9 which is the same as CLSI
for H. influenzae and one dilution higher for S. pneumoniae.
bBreakpoints used are for cefuroxime axetil.
cEUCAST do not give iv breakpoints but dose-specific-susceptible breakpoints are noted for pneumonia: 1.2 g%4, 0.5 mg/L; 2.4 g%4 (or 1.2 g%6),
1 mg/L and 2.4 g%6,2 mg/L.
dTrimethoprim/sulfamethoxazole was tested at a 1:19 trimethoprim to sulfamethoxazole ratio; breakpoints are expressed as the trimethoprim
component.
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(8.2%). Most isolates (n"98; 50.3%) came from adult patients
(13–64 years old), 69 (35.4%) were from children (aged12 years)
and 28 (14.4%) were from elderly patients (aged65 years).
Summary MIC and susceptibility data for all 195 S. pneumoniae
isolates broken down by country of origin are shown in Table 2.
MIC distribution data are given in Table 3.
S. pneumoniae susceptibility in the Slovak Republic
Of the 95 pneumococci collected in the Slovak Republic, 64.2%
were penicillin susceptible by CLSI penicillin intravenous (iv) (non-
meningitis) breakpoints and 61.1% by CLSI penicillin oral
breakpoints or EUCAST breakpoints. All the S. pneumoniae were
susceptible to levofloxacin and moxifloxacin by all breakpoints.
Susceptibility to ceftriaxone was 82.1% by CLSI and PK/PD break-
points, but only 63.2% by EUCAST breakpoints. Susceptibility to
amoxicillin and amoxicillin/clavulanic acid was 65.3% and 80.0%,
respectively, at high-dose PK/PD breakpoints, but reduced to
64.2% by CLSI and low-dose PK/PD breakpoints. Susceptibility to
trimethoprim/sulfamethoxazole was 64.2% by all breakpoints,
and to cefuroxime it was 63.2% by CLSI and PK/PD criteria and
56.8% by EUCAST standards. The other antimicrobials showed sus-
ceptibility rates of,60% (Table 2).
Insufficient isolates were obtained to analyse antimicrobial sus-
ceptibility by specimen source. There was no significant difference
in antimicrobial susceptibility based on patient age (data not
shown).
S. pneumoniae susceptibility in Ukraine
Of the pneumococcal isolates from Ukraine, 97.0% were suscep-
tible to penicillin by CLSI penicillin iv (non-meningitis) breakpoints
and 83.0% were susceptible by CLSI penicillin oral breakpoints or
EUCAST breakpoints. All were susceptible to levofloxacin and moxi-
floxacin by all breakpoints. Ninety-eight percent were also suscep-
tible to ceftriaxone by CLSI and PK/PD breakpoints, with a
reduction to 90.0% by EUCAST breakpoints. Susceptibility to amoxi-
cillin and amoxicillin/clavulanic acid was 97.0% by CLSI and PK/PD
Table 2. MIC and susceptibility data for S. pneumoniae isolates
Susceptibility using indicated breakpoints
MIC (mg/L) CLSI PK/PD EUCAST
Antimicrobial n 50% 90% min max %S %I %R %S %S %I %R
Slovak Republic
amoxicillina 95 0.03 8 0.015 .8 64.2 1.1 34.7 64.2 (65.3) NA NA NA
AMCa 95 0.015 8 0.015 8 64.2 15.8 20.0 64.2 (80.0) NA NA NA
azithromycin 95 .2 .2 0.06 .2 44.2 0.0 55.8 41.1 44.2 0.0 55.8
cefaclor 95 1 .4 0.5 .4 57.9 3.2 39.0 6.3 0.0 6.3 93.7
ceftriaxone 95 0.12 2 0.03 2 82.1 17.9 0.0 82.1 63.2 36.8 0.0
cefuroxime 95 0.12 .4 0.12 .4 63.2 0.0 36.8 63.2 56.8 6.3 36.8
clarithromycin 95 .1 .1 0.015 .1 44.2 0.0 55.8 44.2 44.2 0.0 55.8
erythromycin 95 .0.5 .0.5 0.03 .0.5 44.2 0.0 55.8 44.2 44.2 0.0 55.8
levofloxacin 95 1 1 0.5 2 100 0.0 0.0 100 100 – 0.0
moxifloxacin 95 0.12 0.25 0.06 0.25 100 0.0 0.0 100 100 – 0.0
penicillin (oral) 95 0.06 4 0.06 .4 61.1 3.2 35.8 NA 61.1 3.2 35.8
penicillin (iv non-meningitis) 95 0.06 4 0.06 .4 64.2 31.6 4.2 NA NA NA NA
SXT 95 0.12 .2 0.06 .2 64.2 1.1 34.7 64.2 64.2 1.1 34.7
Ukraine
amoxicillina 100 0.015 1 0.015 8 97.0 0.0 3.0 97.0 (97.0) NA NA NA
AMCa 100 0.015 0.5 0.015 8 97.0 2.0 1.0 97.0 (99.0) NA NA NA
azithromycin 100 0.12 .2 0.03 .2 84.0 0.0 16.0 76.0 84.0 0.0 16.0
cefaclor 100 1 4 0.25 .4 86.0 1.0 13.0 28.0 0.0 28.0 72.0
ceftriaxone 100 0.03 0.5 0.015 2 98.0 2.0 0.0 98.0 90.0 10.0 0.0
cefuroxime 100 0.12 2 0.12 .4 89.0 2.0 9.0 89.0 88.0 0.0 12.0
clarithromycin 100 0.015 .1 0.015 .1 84.0 1.0 15.0 84.0 84.0 1.0 15.0
erythromycin 100 0.03 .0.5 0.03 .0.5 83.0 0.0 17.0 83.0 83.0 0.0 17.0
levofloxacin 100 1 1 1 2 100 0.0 0.0 100 100 – 0.0
moxifloxacin 100 0.12 0.25 0.06 0.5 100 0.0 0.0 100 100 – 0.0
penicillin (oral) 100 0.06 1 0.06 4 83.0 9.0 8.0 NA 83.0 14.0 3.0
penicillin (iv non-meningitis) 100 0.06 1 0.06 4 97.0 3.0 0.0 NA NA NA NA
SXT 100 0.25 .2 0.12 .2 75.0 13.0 12.0 75.0 75.0 13.0 12.0
AMC, amoxicillin/clavulanic acid; SXT, trimethoprim/sulfamethoxazole; S, susceptible; I, intermediate; R, resistant; NA, not applicable.
aAmoxicillin and amoxicillin/clavulanic acid PK/PD susceptibility at high dose shown in parentheses.
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low-dose breakpoints; using high-dose PK/PD criteria susceptibility
to amoxicillin remained at 97.0%, whereas susceptibility to amoxi-
cillin/clavulanic acid increased to 99.0%. Susceptibility by CLSI
breakpoints to the oral cephalosporins and the macrolides ranged
from 83.0% for erythromycin to 89.0% for cefuroxime.
Susceptibility was the same or similar by PK/PD and EUCAST break-
points except for susceptibility of isolates to cefaclor, which
showed values of 28.0% using PK/PD criteria and 0% using EUCAST
standards. Trimethoprim/sulfamethoxazole was the only agent to
which,80% of isolates were susceptible (75.0% by all three break-
points) (Table 2).
Antimicrobial susceptibility using CLSI criteria was compared
across specimen sources and age groups. The only statistically sig-
nificant difference observed was for the macrolides between iso-
lates from paediatric patients (n"27; 70.4% susceptible to all
three macrolides) and adults (n"65; 89.2% susceptible, P"0.03)
and for cefaclor between isolates from paediatric patients (70.4%
susceptible) and adults (90.8% susceptible, P"0.02).
Antimicrobial susceptibility of S. pneumoniae by
penicillin susceptibility
Among the 195 S. pneumoniae isolates from both countries,
141 (72.3%) were penicillin susceptible (PSSP), 12 (6.2%) were
penicillin intermediate (PISP) and 42 (21.5%) were penicillin
resistant (PRSP) according to CLSI oral breakpoints. PSSP and
PRSP sub-groups had a sample size .20 and were compared for
susceptibility to other antimicrobial agents (Figure 1). Among PSSP
isolates, susceptibility to the fluoroquinolones, amoxicillin, amoxi-
cillin/clavulanic acid, cefuroxime and ceftriaxone was 100%, to
cefaclor it was 97.9%, to trimethoprim/sulfamethoxazole 90.8%
and to the macrolides 80.9% (using CLSI criteria). The fluoroquino-
lones also maintained 100% activity against PRSP isolates, but sus-
ceptibility to the other agents was significantly lower than in PSSP
isolates (P,0.0001), with rates ranging from 0% to 12% to all re-
maining agents except ceftriaxone (54.8%).
H. influenzae isolates
A total of 194 H. influenzae isolates were collected from the three
centres in the Slovak Republic and Ukraine from 2014 to 2016.
Specimen origins of the isolates included sputum (n"91; 46.9%),
sinuses (n"43; 22.2%), bronchoalveolar lavage (n"30; 15.5%),
endotracheal aspirate (n"14, 7.2%) and middle ear effusion
(n"10, 5.2%). Six isolates (3.1%) were from an undisclosed re-
spiratory source. Most isolates (n"116; 59.8%) came from adult
patients, 52 (26.8%) were from children and 26 (13.4%) were from
elderly patients. The rate of b-lactamase-positive isolates was
Table 3. MIC distribution data for S. pneumoniae isolates
Antimicrobial
Number of isolates at MIC (mg/L)
0.015 0.03 0.03 0.06 0.06 0.12 0.12 0.25 0.5 .0.5 1 .1 2 .2 4 .4 8 .8
Slovak Republic (n"95)
amoxicillin 15 36 7 2 1 1 32 1
AMC 52 5 1 1 1 1 15 19
azithromycin 1 38 3 53
cefaclor 6 49 3 1 36
ceftriaxone 34 1 22 2 1 18 17
cefuroxime 52 2 6 2 33
clarithromycin 35 7 53
erythromycin 41 1 53
levofloxacin 1 90 4
moxifloxacin 1 59 35
penicillin 58 1 1 1 30 4
SXT 2 53 5 1 1 33
Ukraine (n"100)
amoxicillin 51 32 2 3 1 6 2 3
AMC 84 2 1 1 1 1 7 2 1
azithromycin 4 13 59 8 16
cefaclor 2 26 58 1 5 8
ceftriaxone 3 78 3 3 1 2 8 2
cefuroxime 88 1 2 6 3
clarithromycin 73 10 1 1 2 13
erythromycin 79 4 17
levofloxacin 91 9
moxifloxacin 21 58 20 1
penicillin 83 2 3 1 3 5 3
SXT 49 11 15 13 12
AMC, amoxicillin/clavulanic acid; SXT, trimethoprim/sulfamethoxazole.
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5.1% in the Slovak Republic (5/98) and 7.3% in Ukraine (7/96).
Seven isolates from the Slovak Republic (7.1%) and one from
Ukraine (1.0%) were b-lactamase-negative-ampicillin-resistant
(BLNAR) by CLSI breakpoints (ampicillin MIC 4 mg/L), and eight
from the Slovak Republic (8.2%) and one from Ukraine (1.0%) were
BLNAR by EUCAST breakpoints (ampicillin MIC2 mg/L).
Summary MIC and susceptibility data for all 194 H. influenzae
isolates broken down by country of origin are shown in Table 4.
MIC distribution data are given in Table 5.
H. influenzae susceptibility in the Slovak Republic
All isolates of H. influenzae from the Slovak Republic were suscep-
tible to levofloxacin and moxifloxacin by all three breakpoint
guidelines as well as to ceftriaxone by CLSI and PK/PD breakpoints
(but susceptibility was reduced to 96.9% by EUCAST criteria).
Susceptibility testing also resulted in 100% susceptibility to amoxi-
cillin/clavulanic acid using CLSI and PK/PD high-dose breakpoints.
However, CLSI guidelines state that BLNAR strains should be con-
sidered resistant to amoxicillin/clavulanic acid, cefuroxime and
cefaclor, even if they appear susceptible in vitro.7 This reduces the
percentage susceptible to amoxicillin/clavulanic acid to 92.9%, the
same rate as obtained using PK/PD low-dose and EUCAST break-
points. Similarly, susceptibility to cefuroxime was reduced from
100% to 92.9% by CLSI criteria after adjusting for BLNAR, and sus-
ceptibility to cefaclor was reduced from 89.8% to 86.7%.
Susceptibility to both agents was dramatically lower using the
other breakpoints (82.7% and 1.0% by PK/PD and EUCAST criteria,
respectively, for cefuroxime, and 0% by PK/PD breakpoints for
cefaclor). Susceptibility to ampicillin and amoxicillin was 86.7%, to
trimethoprim/sulfamethoxazole it was 77.6% by all available
breakpoints; and to clarithromycin 34.7% by CLSI standards and
0% by PK/PD and EUCAST criteria.
Antimicrobial susceptibility was compared by specimen source
and age group with no significant difference observed (data not
shown).
H. influenzae susceptibility in Ukraine
In Ukraine, susceptibility of H. influenzae (n"96) was 100% to cef-
triaxone, levofloxacin and moxifloxacin by all three breakpoint
0
20
40
60
80
100
%
 S
us
ce
pt
ib
le
 (9
5%
 C
I)
PSSP (n=141) PRSP (n=42)
Le
vo
flo
xa
cin
Mo
xif
lox
ac
in
Az
ith
ro
m
yc
in*
Er
yt
hr
om
yc
in*
Cla
rit
hr
om
yc
in*
Tr
im
et
ho
pr
im
/su
lfa
m
et
ho
xa
zo
le*
Am
ox
ici
llin
*
Am
ox
ici
llin
/cl
av
ula
nic
 ac
id*
Ce
fu
ro
xim
e*
Ce
ftr
iax
on
e*
Ce
fa
clo
r*
Figure 1. Percentage susceptibility rates (with 95% CI) using CLSI criteria for antimicrobials against all S. pneumoniae according to susceptibility to
penicillin (oral). *PSSP significantly more susceptible than PRSP isolates (P,0.0001). PSSP, penicillin-susceptible S. pneumoniae; PRSP, penicillin-resist-
ant S. pneumoniae.
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guidelines. Susceptibility to amoxicillin/clavulanic acid in vitro was
also 100% by CLSI breakpoints and high-dose PK/PD breakpoints,
but because one isolate was a BLNAR strain, susceptibility accord-
ing to CLSI standards was slightly reduced to 99.0%. Susceptibility
was 95.8% using low-dose PK/PD or EUCAST breakpoints. Similarly,
susceptibility to cefuroxime was slightly reduced from 97.9% to
96.9% after adjusting for BLNAR using CLSI criteria; susceptibility
was reduced much further using the other breakpoint criteria
(70.8% by PK/PD and 0% by EUCAST standards). Susceptibility to
cefaclor by CLSI criteria did not change as one BLNAR isolate had
already tested resistant to cefaclor (87.5%), but susceptibility was
0% using the PK/PD breakpoint. A similarly dramatic difference be-
tween breakpoints was again seen for clarithromycin (61.5% by
CLSI criteria, 0% by PK/PD and 2.1% by EUCAST). Susceptibility to
trimethoprim/sulfamethoxazole was seen in 60.4% of isolates by
all breakpoints.
Insufficient isolates were obtained to analyse antimicrobial sus-
ceptibility by specimen source or age.
Discussion
The countries in eastern Europe studied for this report showed sub-
stantial variability in the susceptibility of S. pneumoniae, similar to
findings in other regions of the world that have been studied with
the SOAR programme.2–5 S. pneumoniae isolates collected in
Ukraine (n"100) showed higher susceptibility than those in the
Slovak Republic, with rates97% for all studied agents except oral
penicillin, macrolides and cefaclor (between 83% and 86% suscep-
tible) as well as cefuroxime (89%) and trimethoprim/sulfameth-
oxazole (75%). In the Slovak Republic, the fluoroquinolones
remained 100% active, but of the other tested agents only cef-
triaxone exceeded 80% susceptibility by CLSI criteria. Penicillin
(oral and iv), amoxicillin, amoxicillin/clavulanic acid, cefaclor,
cefuroxime and trimethoprim/sulfamethoxazole showed suscepti-
bility between 58% and 64%, and the macrolides only 44%. There
was significantly lower antimicrobial susceptibility (CLSI break-
points) seen with isolates from the Slovak Republic compared with
Table 4. MIC and susceptibility data for H. influenzae isolates
Susceptibility using indicated breakpoints
MIC (mg/L) CLSI PK/PD EUCAST
Antimicrobial n 50% 90% min max %S %I %R %S %S %I %R
Slovak Republic
amoxicillina 98 2 8 2 .128 NA NA NA 86.7 (89.8) 86.7 – 13.3
AMCa,b 98 0.5 2 0.25 4 100 (92.9) – 0.0 (7.1) 92.9 (100) 92.9 – 7.1
ampicillin 98 0.25 4 0.06 .128 86.7 1.0 12.2 – 86.7 – 13.3
azithromycin 98 2 2 1 4 100 – – 0.0 0.0 100 0.0
cefaclorb 98 4 16 1 16 89.8 (86.7) 10.2 (6.1) 0.0 (7.1) 0.0 NA NA NA
ceftriaxone 98 0.03 0.06 0.03 0.25 100 – – 100 96.9 – 3.1
cefuroximeb 98 0.5 2 0.06 4 100 (92.9) 0.0 0.0 (7.1) 82.7 1.0 81.6 17.4
clarithromycin 98 16 16 8 .16 34.7 59.2 6.1 0.0 0.0 100 0.0
levofloxacin 98 0.015 0.03 0.008 0.06 100 – – 100 100 – 0.0
moxifloxacin 98 0.015 0.015 0.008 0.06 100 – – 100 100 – 0.0
SXT 98 0.25 .2 0.03 .2 77.6 3.1 19.4 77.6 77.6 0.0 22.5
Ukraine
amoxicillina 96 2 4 2 .128 NA NA NA 87.5 (91.7) 87.5 – 12.5
AMCa,b 96 0.5 2 0.25 4 100 (99.0) – 0.0 (1.0) 95.8 (100) 95.8 – 4.2
ampicillin 96 0.25 1 0.12 .128 91.7 0.0 8.3 – 91.7 – 8.3
azithromycin 96 2 2 0.12 8 97.9 – – 2.1 2.1 95.8 2.1
cefaclorb 96 4 16 1 32 87.5 6.3 6.3 0.0 NA NA NA
ceftriaxone 96 0.03 0.03 0.03 0.12 100 – – 100 100 – 0.0
cefuroximeb 96 1 4 0.25 8 97.9 (96.9) 2.1 0.0 (1.0) 70.8 0.0 70.8 29.2
clarithromycin 96 8 16 1 .16 61.5 37.5 1.0 0.0 2.1 97.9 0.0
levofloxacin 96 0.015 0.03 0.008 0.06 100 – – 100 100 – 0.0
moxifloxacin 96 0.015 0.03 0.008 0.12 100 – – 100 100 – 0.0
SXT 96 0.25 .2 0.015 .2 60.4 2.1 37.5 60.4 60.4 0.0 39.6
AMC, amoxicillin/clavulanic acid; SXT, trimethoprim/sulfamethoxazole; S, susceptible; I, intermediate; R, resistant; NA, not applicable; min, minimum;
max, maximum.
aAmoxicillin and amoxicillin/clavulanic acid PK/PD susceptibility at high dose shown in parentheses.
bIn clinical settings, isolates of BLNAR are considered resistant to amoxicillin/clavulanic acid, cefaclor and cefuroxime. If clinical susceptibility to these
agents was reduced due to BLNAR, data are shown in parentheses.
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isolates from Ukraine to penicillin (iv), amoxicillin, amoxicillin/clav-
ulanic acid, cefuroxime, cefaclor or macrolides (P,0.0001), cef-
triaxone (P"0.002) and oral penicillin (P" 0.001).
Few data on antimicrobial susceptibility have been published
for these countries. The most recent data available were gener-
ated through the European Antimicrobial Resistance Surveillance
Network (EARS-Net);10 however, only the Slovak Republic partici-
pated and only invasive (blood and CSF) isolates are included in
EARS-Net surveillance. Nevertheless the EARS-Net data of 22.2%
penicillin non-susceptibility in 201510 confirmed our findings of low
susceptibility to penicillin in the Slovak Republic even though the
non-susceptibility rate was higher in the current study of respira-
tory isolates (38.9%). Interestingly, Marchese and Schito described
high resistance rates among respiratory S. pneumoniae isolates
from the Slovak Republic over 15 years ago: data from the
Alexander Project from 1997 showed penicillin resistance of 26.7%
and macrolide resistance of 13.3%.11 Riedel et al.12 also reported
high non-susceptibility rates to penicillin (52.3%) and erythro-
mycin (36.4%) in isolates from community-acquired respiratory
tract infections collected in 2004–05 in the Slovak Republic. The
same study showed that antimicrobial use in the Slovak Republic
between 1998 and 2004 was third highest among 15 European
countries, thus providing evidence for the association between
antimicrobial resistance and increased use of antibiotics.12,13 In a
more recent study of antibiotic consumption in 2011 in the broader
European region, the Slovak Republic also ranked high (15th
among 42 countries) in total antibiotic use.14
Ukraine was not included in any of these studies, but data from
an earlier SOAR report are available for comparison.15 Susceptibility
among the S. pneumoniae isolates from 2014 to 2016 included in
the current study was similar to the S. pneumoniae isolates col-
lected in 2011–13, with only a small decrease of between 2 and
5 percentage points for most antimicrobial agents. For example,
amoxicillin/clavulanic acid showed susceptibility by CLSI criteria of
100% in 2011–13 compared with 97.0% in the current study, and
the respective values for oral penicillin were 87.3% and 83.0%. The
exception is trimethoprim/sulfamethoxazole, where susceptibility
was very low in 2011–13 (9.7%),11 but 75% in the current study for
2014–16. It would be interesting to monitor these fluctuations in
future studies.
In contrast to S. pneumoniae, antimicrobial activity against
H. influenzae was fairly homogeneous between the two countries.
Susceptibility to amoxicillin/clavulanic acid, ceftriaxone, cefurox-
ime, azithromycin and the fluoroquinolones was.90% by CLSI cri-
teria. Susceptibility to clarithromycin was lower and more variable
(35% in the Slovak Republic compared with 61.5% in Ukraine), as
was trimethoprim/sulfamethoxazole (77.6% in the Slovak Republic
compared with 60.4% in Ukraine). The ampicillin resistance rate
was 12.2% in the Slovak Republic, where the b-lactamase rate was
5.1% and an additional 7.1% of isolates were BLNAR. Ampicillin re-
sistance was lower in Ukraine (8.3%) due to a lower b-lactamase
rate (7.3%) and a low rate of BLNAR isolates (1.0%). These rates
were also low in Ukraine in 2011–13, with a b-lactamase rate of
4.5% and no BLNAR isolates.15 Furthermore, susceptibility rates of
Table 5. MIC distribution data for all H. influenzae isolates
Antimicrobial
Number of isolates at MIC (mg/L)
0.004 0.008 0.015 0.015 0.03 0.03 0.06 0.06 0.12 0.25 0.5 0.5 1 1 2 2 .2 4 8 16 .16 32 .32 64 128 .128
Slovak Republic (n"98)
amoxicillin 85 3 5 5
AMC 11 50 20 10 7
ampicillin 1 12 54 18 1 7 1 1 3
azithromycin 16 78 4
cefaclor 5 41 30 12 10
ceftriaxone 88 1 6 3
cefuroxime 1 1 54 25 8 9
clarithromycin 34 58 6
levofloxacin 47 12 35 4
moxifloxacin 18 73 6 1
SXT 8 29 10 29 3 19
Ukraine (n"96)
amoxicillin 84 4 1 1 4 2
AMC 10 39 20 23 4
ampicillin 7 55 26 1 1 1 2 3
azithromycin 2 2 8 36 43 3 2
cefaclor 5 22 36 21 6 6
ceftriaxone 93 2 1
cefuroxime 3 32 33 18 8 2
clarithromycin 2 6 51 36 1
levofloxacin 9 59 21 7
moxifloxacin 20 55 16 4 1
SXT 1 7 15 14 21 2 36
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H. influenzae in Ukraine were similar in the current study compared
with the results in 2011–13, with the activity of most antimicrobial
agents either still at 100% or only about 2 percentage points lower
than in the earlier study. The exception is clarithromycin, where
susceptibility was 61.5% using CSLI criteria in 2014–16 but 98.5%
in 2011–13.15 Information on H. influenzae is sparse in the litera-
ture for the Slovak Republic. Interestingly, b-lactamase rates found
through the Alexander Project 20 years ago were similar to those
in our current study (5% in 1996 and 1997 in the Slovak
Republic).11 Furthermore, the Slovak Republic, which had the high-
est BLNAR rate in the current study, was one of only four European
countries where such isolates were found in 1997 (albeit at a very
low rate).11
Although antimicrobial activity against H. influenzae was fairly
homogeneous in the two countries, this was not the case when
comparing susceptibility rates obtained using different breakpoints.
For example, whereas.97% of isolates were susceptible to azithro-
mycin using CLSI breakpoints, only 2.1% were susceptible using
PK/PD and EUCAST criteria. Similarly, large differences were found
for cefaclor between CLSI and PK/PD breakpoints and for cefuroxime
between CLSI/PK/PD and EUCAST standards. Furthermore, although
differences between breakpoints were small for most antimicrobial
agents for S. pneumoniae, they were substantial for cefaclor. For ex-
ample, in Ukraine 86.0% of S. pneumoniae isolates were susceptible
by CLSI criteria, 28.0% by PK/PD and 0% using EUCAST standards.
These differences are confusing for clinicians, but also hamper the
use of surveillance data for research and public health efforts like
antimicrobial stewardship.
This study’s main limitation stems from having to draw conclu-
sions about a country’s antimicrobial susceptibility levels using
data from just one or two hospital sites. It is reassuring that the re-
sults for Ukraine were very similar in the current study, which used
two sites, to the earlier SOAR report, with eight sites. Nevertheless,
more solid susceptibility rates can no doubt be achieved if surveil-
lance is undertaken at more hospitals in each country, whether in-
dependently or as part of a national, regional or even international
surveillance programme. Larger surveillance studies, such as
SOAR, have the advantage of being able to employ a consistent
methodology, which facilitates comparison between regions as
well as trend analyses over time, but even surveillance at a single
hospital can help local clinicians in selecting antibiotics for empir-
ical therapy. In this study, data from just one or two hospitals per
country were able to confirm a pattern of resistance already seen
many years ago: high resistance of S. pneumoniae in the Slovak
Republic compared with its neighbour Ukraine to the east. Regular
monitoring and publication of such resistance data are not only
critical for effective empirical therapy but can also be used to help
shape antimicrobial stewardship strategies in an effort to lower
historically high resistance rates.
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